Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

A. Mark Fendrick, MD

Articles by A. Mark Fendrick, MD

Cost-Effective Use of NSAIDs: Issues Pertinent to Coxib Use in Managed Care

ByA. Mark Fendrick, MD

November 1st 2002

A Word From the New Editors

ByA. Mark Fendrick, MD,Michael E. Chernew, PhD

September 1st 2002

Coronary Artery Bypass Grafting in Octogenarians: Clinical and Economic Outcomes at Community-Based Healthcare Facilities

ByBrahmajee K. Nallamothu, MD, MPH,Sanjay Saint, MD, MPH,Kim A. Eagle, MD,Kenneth M. Langa, MD, PhD,A. Mark Fendrick, MD,Robert V. Hogikyan, MD,

August 1st 2002

Diagnostic Testing or Empirical Neuraminidase Inhibitor Therapy for Patients with Influenza-Like Illness: What a Difference a Day Makes

BySusan G. Blitz, MD, MPH,Peter Cram, MD,Michael E. Chernew, PhD,Arnold S. Monto, MD,A. Mark Fendrick, MD

March 1st 2002

A New Method for Determining Patient Payments for Outpatient Drugs

ByDana P. Goldman, PhD,A. Mark Fendrick, MD,Dean G. Smith, PhD,Michael E. Chernew, PhD

February 1st 2002

A Benefit-Based Copay for Prescription Drugs: Patient Contribution Based on Total Benefits, Not Drug Acquisition Cost

ByA. Mark Fendrick, MD,Dean G. Smith, PhD,Michael E. Chernew, PhD,Sonali N. Shah, MBA, MPH

September 1st 2001

Decomposing Pharmaceutical Cost Growth in Different Types of Health Plans

ByMichael E. Chernew, PhD,Dean G. Smith, PhD,Duane M. Kirking, PharmD, PhD,A. Mark Fendrick, MD

July 1st 2001

The Costs of Cancer to a Major Employer in the United States: A Case-Control Analysis

ByArnold Barnett, PhD,Howard Birnbaum, PhD,Pierre-Yves Cremieux, PhD,A. Mark Fendrick, MD,Mitchell Slavin, PharmD

November 1st 2000

Access to Innovative Treatment of Erectile Dysfunction: Clinical, Economic, and Quality-of-Life Considerations

ByA. Mark Fendrick, MD

August 1st 2000

"We Got Mail": Electronic Communication Between Physicians and Patients

ByCheryl A. Moyer, MPH,David T. Stern, MD, PhD,Steven J. Katz, MD, MPH,A. Mark Fendrick, MD

December 1st 1999

Diagnostic Testing for Influenza: Review of Current Status and Implications of Newer Treatment Options

ByPeter Cram, MD,Susan G. Blitz, MD, MPH,Arnold Monto, MD,A. Mark Fendrick, MD

December 1st 1999

Differences in Physician Compensation for Cardiovascular Services by Age, Sex, and Race

ByHarlan M. Krumholz, MD,A. Mark Fendrick, MD,Christianna Williams, MA,William M. Hynes

April 1st 1997

Understanding the Behavioral Response to Medical Innovation

ByA. Mark Fendrick, MD,Michael E. Chernew, PhD,Richard Hirth, PhD,Devidas Menon, PhD, MHSA

August 1st 1996

Correspondence regarding, "Diagnosis and Eradication of Helicobacter pylori in the Management of Peptic Ulcer Disease: A Decision Analysis Model"

ByBernard S. Bloom, PhD,Michael E. Chernew, PhD,Richard Hirth, PhD,A. Mark Fendrick, MD,Reply by Robert J. Rubin, MD,Elisa F. Cascade, MBA,David A. Peura, MD,C. Mel Wilcox, MD,Daniel N.

June 1st 1996

Trending on AJMC

Tec-Dara Demonstrates Superior 3-Year PFS vs Standard Therapy in Functional High-Risk Myeloma: Rahul Banerjee, MD

MRD-Guided CLL Treatment Duration: Personalization or Malpractice?

Global Hematology Trials Ensure Research Stays Applicable, Flexible, Patient-Centered

Blinatumomab Improves Outcomes, Toxicity in High-Risk Pediatric ALL: Martin Schrappe, MD, PhD

frontMIND Trial Shows PFS Benefit With Tafasitamab, Lenalidomide Combo in High-Risk DLBCL: Umberto Vitolo, MD